



---

---

**TEXAS STATE BOARD OF PHARMACY**

---

---

**1601 Congress Ave, Room 2.013  
Austin, Texas**

**Tuesday, November 5, 2024**

**MINUTES<sup>1</sup>**

**BOARD BUSINESS MEETING**

**Tuesday, November 5, 2024**

President Julie Spier, R.Ph., called the meeting to order at 9:02 a.m. Other Board Members present were Vice President Bradley A. Miller, Ph.T.R.; Treasurer Jenny Downing Yoakum, R.Ph.; Rick Fernandez, R.Ph.; Donnie Lewis, R.Ph.; Randy Martin, Pharm.D., R.Ph.; Donna Montemayor, R.Ph.; Ian Shaw; and Suzette Tijerina, R.Ph.

Board members Garrett Marquis and Rick Tisch were not in attendance.

Staff present were Daniel Carroll, Pharm.D., R.Ph., Executive Director/Secretary; Megan Holloway, General Counsel; Caroline Hotchkiss, Director of Enforcement; John Griffith, Litigation Counsel; Ann Driscoll, Ph.T.R., Director of Operations; Ruben Leal, Budget Analyst; David Meryman, Ph.T.R., Prescription Monitoring Program Manager; Eamon Briggs, Deputy General Counsel; and Lily Moreno, Executive Assistant.

**A. Announcements**

Dr. Carroll welcomed and introduced new Board staff member Rafael Pimentel Pinto, Director of IT.

President Spier made general announcements, including concerning continuing education credit for attending the Board Meeting, and reviewed the meeting procedures.

President Spier thanked Board Member Garrett Marquis for his service to the Board, and reported a request has been made for another individual to complete the appointment as a public member in his place.

---

<sup>1</sup>See agenda and corresponding attachments for supporting materials.

**B. Discussion and Approval of Minutes of Previous Meetings (Item B)**

Following discussion, the motion was made by Mr. Martin to approve the minutes of the Board Business Meeting held August 6, 2024. The motion was seconded by Mr. Lewis and passed unanimously.

**C. Discussion of and Possible Action Regarding Rules**

Final Adoption of Rules

- Rules Concerning Prescription Pick Up Locations (§291.9) (Item C.1.1)

Mr. Griffith explained that the Board voted to propose the amendments to §291.9 during its August 6, 2024, meeting. The proposed amendments were published in the September 20, 2024, issue of the *Texas Register*.

Mr. Griffith directed the Board's attention to amendments to §291.9 and explained that the amendments clarify that U.S. Mail is a type of common carrier.

Written comments were received from Craig Chapman, R.Ph., expressing concern that the amendments may be unnecessary and suggesting alternative language for consistency with other Board rules.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Ms. Montemayor to approve for adoption, by Board Order, the amendments to §291.9, as presented. The motion was seconded by Mr. Fernandez and passed unanimously.

- Rules Concerning Community Pharmacy (Class A) Operational Standards (§291.33) (Item C.1.2)

Mr. Griffith explained that the Board voted to propose the amendments to §291.33 during its August 6, 2024, meeting. The proposed amendments were published in the September 20, 2024, issue of the *Texas Register*.

Mr. Griffith directed the Board's attention to amendments to §291.33 and explained that the amendments clarify a recordkeeping requirement for a donated prescription drug dispensed under Chapter 442, Health and Safety Code, in accordance with House Bill 4332 of the 88th Legislative Session.

Written comments were received from George Wang, Ph.D., with SIRUM, in support of the amendments.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Lewis to approve for adoption, by

Board Order, the amendments to §291.33, as presented. The motion was seconded by Mr. Miller and passed unanimously.

- Rules Concerning Pharmacies Compounding Sterile Preparations (§291.133) (Item C.1.3)

Mr. Briggs explained that the Board voted to propose the amendments to §291.133 during its August 6, 2024, meeting. The proposed amendments were published in the September 20, 2024, issue of the *Texas Register*.

Mr. Briggs directed the Board's attention to §291.133 and explained that the amendments update the personnel, environment, compounding garbing, environmental testing, sterility testing, recall procedure, and recordkeeping requirements for pharmacies compounding sterile preparations. He also explained that a revised version had been prepared by Board staff which included language recommended by the Compound Rules Advisory Group sterile subcommittee that was inadvertently omitted and included revisions made by Board staff to reflect the sterile subcommittee's intent concerning air sampling requirements.

Written comments were received from the following:

- Cindy Polk Dumas, R.Ph., AIS Healthcare, requesting that the Board adopt USP <797> (2023), as written;
- Tera McConnell, R.Ph., PETNET Solutions, with suggested changes to the proposed amendments;
- Ryan Roux, R.Ph., and Kelley Reece, R.Ph., The University of Texas MD Anderson Cancer Center, with suggested changes to the proposed amendments;
- Stephen Snow, Bendin Sumrall & Ladner, LLC, with suggested changes to the proposed amendments;
- Scott Brunner, CEO, Alliance for Pharmacy Compounding, expressing support for some of the amendments and with suggested changes to the proposed amendments;
- Mindy Sauter, McGuire Woods LLP, with suggested changes to the proposed amendments;
- Jeffrey L. Wagner, R.Ph., Texas Society of Health-System Pharmacy, expressing support for the majority of the amendments and with suggested changes to the proposed amendments; and
- John Daniel, R.Ph., with suggested changes to the proposed amendments.

Oral comments were received from the following:

- RoxAnn Dominguez, Pharm.D., R.Ph., CEO, and Jobby John, Pharm.D., R.Ph., President, Texas Pharmacy Association, in opposition to the proposed amendments and with suggested changes;

- Katie Johnston, Austin Compounding Pharmacy, in support of the proposed amendments;
- Mr. Wagner, reiterating his written comments;
- Mr. Snow, reiterating his written comments;
- Ms. Sauter, reiterating her written comments; and
- Matt Martin, Pharm.D., BCPS, with suggested changes to the proposed amendments.

President Spier recessed the meeting at 10:25 a.m.

President Spier reconvened the meeting at 10:42 a.m.

President Spier opened discussion concerning the proposed amendments to §291.133, including a review of proposed changes to definitions, personnel, and operational standards.

President Spier recessed the meeting at 11:52 a.m.

President Spier reconvened the meeting at 12:32 p.m.

Discussion continued concerning the proposed amendments to §291.133, with a review of proposed changes to beyond-use-dating.

**D. Discussion of and Possible Action Concerning Pilot Projects**

- Report on Pilot Project Concerning Residential Delivery of Prescription Drugs by Means of Drone Delivery Service (D.1)

President Spier directed the Board's attention to a report from Amazon Pharmacy regarding the pilot project concerning residential delivery of prescription drugs by means of drone delivery service.

President Spier recognized Ehihimen Okogbo, R.Ph., Pharmacist-in-Charge of Amazon Pharmacy #008; and Meaghan Atkinson, Senior Corporate Counsel, Amazon Legal, who reviewed the report and requested an extension of the pilot project through September 2025.

President Spier requested the final report for the pilot project be received on January 13, 2025, to allow time for the pilot project task force to consider the recommendation and any potential rule changes before the February 4, 2025, Board meeting. She clarified that this would allow Amazon Pharmacy #008 to continue operating under the pilot project rule exceptions until the February Board meeting, but no extension would be considered at this time. Ms. Holloway further clarified that an extension to the rule exceptions beyond the 18-month pilot project limit cannot be granted unless the Board is engaged in rulemaking.

President Spier recognized Freddy Warner, Chief Government Relations Officer with Memorial Hermann Health System; Binita Patel, Vice President-Pharmacy Services with Memorial Hermann Health System; Conor French, Chief Regulatory Officer with Zipline; and Keval Patel, General Counsel with Zipline, who provided oral comments concerning future plans between their organizations for a drone delivery service strategy. Additionally, Zipline provided information concerning their pharmaceutical drone delivery ventures outside of Texas.

**F. Discussion of and Possible Action Concerning the Following Reports and Discussions**

- Professional Recovery Network (PRN)
  - Ms. Hotchkiss discussed performance measures regarding the number of individuals participating in the peer assistance program for FY2024 (September 1, 2023 – August 31, 2024). (Item F.2.1)
  - President Spier recognized Will Turney, LMSW, PRN Case Manager. Mr. Turney directed the Board's attention to the PRN expense report for FY2024 (September 1, 2023 – August 31, 2024) and reviewed PRN activities for the Board. (Item F.2.2)

**C. Discussion of and Possible Action Regarding Rules, continued**

Final Adoption of Rules, continued

- Rules Concerning Pharmacies Compounding Sterile Preparations (§291.133) (Item C.1.3), continued

Discussion continued concerning the proposed amendments to §291.133, including a review of proposed changes to environmental testing, quality control, records, and recall procedures.

Rule Review

Mr. Griffith directed the Board's attention to the Board Rule Review Plan for FY2022-FY2025 (Item C.2).

- For Proposal
  - Chapter 297 Concerning Pharmacy Technicians (§§297.1 – 297.11) (Item C.2.1.1)
  - Chapter 291 Concerning Pharmacies (Services Provided by Pharmacies) (§§291.120 – 291.121, 291.123, 291.125, 291.127, 291.129, 291.131, and 291.133) (Item C.2.1.2)

- Chapter 291 Concerning Pharmacies (Other Classes of Pharmacy) (§§291.151 and 291.153) (Item C.2.1.3)

Following discussion, in accordance with Government Code §2001.039, the motion was made by Mr. Lewis to approve for adoption, as presented, the review of Chapter 297 Concerning Pharmacy Technicians (§§297.1 – 297.11), Chapter 291 Concerning Pharmacies (Services Provided by Pharmacies) (§§291.120 – 291.121, 291.123, 291.125, 291.127, 291.129, 291.131, and 291.133), and Chapter 291 Concerning Pharmacies (Other Classes of Pharmacy) (§§291.151 and 291.153). The motion was seconded by Ms. Montemayor and passed unanimously.

**E. Discussion of and Possible Action Concerning Reports of Committees/ Task Forces**

- Report on Prescription Monitoring Program (PMP) Advisory Committee (Item E.1)

Dr. Carroll reported that the PMP Advisory Committee had not met since the previous Board meeting, and that the next meeting has not yet been scheduled.

- Report on Interagency Prescription Monitoring Program Work Group (Item E.2)

Dr. Carroll reported that the Interagency Prescription Monitoring Program Work Group had not met since the previous Board meeting, and the next meeting had not yet been scheduled.

**F. Discussion of and Possible Action Concerning the Following Reports and Discussions, continued**

- Financial Report
  - Review of FY2024 Expenditures (Item F.1.1)

Mr. Leal reviewed the expenditures for FY2024 (September 1, 2023 – August 31, 2024) for the Board.

- Review of Board Member Travel Budget (Item F.1.2)

Mr. Leal reviewed the Board Member Travel Budget for FY2024 (September 1, 2023 – August 31, 2024).

- Consideration of Material Changes to Contracts for Goods and Services Awarded Under Chapter 2155 of Texas Government Code (Item F.1.3)

Mr. Leal reviewed the list of updated contracts for goods and services for the fourth quarter of FY2024 (June 1, 2024 – August 31, 2024).

- Update on Legislative Appropriations Request for FY2026-2027 (Item F.1.4)

Ms. Driscoll reported that the Legislative Appropriations Request for FY2026-2027 was filed on time and was posted on the Board website.

- Report on Appeals from State Office of Administrative Hearing Cases and Other Court Actions (Item F.4)

Ms. Holloway reported that there have been no updates since the last meeting concerning the lawsuit filed by Lightcare Rx, LLC (Texas Pharmacy License #32609) and the pharmacist-in-charge, Leila Elahianboroujeni (Pharmacist License #64241), in the Travis County District Court, appealing the entry of the Board Orders entered in May 2022.

- Report on Prescription Monitoring Program (Item F.3)

Mr. Meryman reviewed the Prescription Monitoring Program (PMP) data for FY2024 (September 1, 2023 – August 31, 2024).

#### **G. Consideration of and Possible Action Concerning Enforcement Reports**

- Report on Complaints Closed and Dismissed During the Previous Quarter (Item G.1)

Ms. Hotchkiss reported on complaints dismissed and closed during FY2024 (September 1, 2023 – August 31, 2024). The report also included a comparison of complaints closed with disciplinary orders to those closed without disciplinary orders and a comparison of quarterly averages for FY2024 to the quarterly averages for FY2023, as well as percentage change from FY2023 to FY2024.

- Report on Status of Active/Pending Complaints (Item G.2)

Ms. Hotchkiss reviewed the *Report on Status of Active/Pending Complaints* for the Board.

## H. Disciplinary Orders

- Report on Agreed Board Orders and Board Orders Entered by Executive Director (Item H.2)
  - The Board reviewed 14 Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from August 15, 2024, through November 1, 2024.
  - The Board reviewed 4 Agreed Board Orders concerning pharmacies and pharmacists that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from August 15, 2024, through November 1, 2024.
  - The Board reviewed 3 Board Orders concerning pharmacies that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from August 22, 2024, through November 1, 2024.
  - The Board reviewed 2 Confidential Agreed Board Order concerning pharmacists that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from September 4, 2024, through November 1, 2024.
- Discussion of and Action on Proposed Agreed Board Orders, Proposed Default Board Orders, and Proposed Remedial Plans (Items H.3 and H.4)

The Board reviewed the alleged violations, as well as the recommended sanctions for each of the following:

- 19 proposed Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees who appeared for an Informal Conference;
- 6 proposed Default Board Order concerning a pharmacy technician who did not appear for an Informal Conference;
- 9 proposed Agreed Board Orders concerning pharmacies and pharmacists (Alternative Resolutions);
- 12 proposed Agreed Board Orders concerning pharmacies and pharmacists who appeared for an Informal Conference;



- 1 proposed Default Board Order concerning a pharmacy who did not appear for an Informal Conference;
- 2 proposed Default Board Orders concerning a pharmacy and a pharmacist (Following State Office of Administrative Hearings);
- 1 proposed Confidential Agreed Board Order concerning a pharmacist (Alternative Resolutions);
- 2 proposed Confidential Agreed Board Orders concerning pharmacists who appeared for an Informal Conference;
- 10 proposed Remedial Plans concerning pharmacies and pharmacists (Alternative Resolutions); and
- 8 proposed Remedial Plans concerning pharmacies and pharmacists who attended an Informal Conference.

The motion was made by Ms. Montemayor to approve the proposed Disciplinary Orders and Remedial Plans, as presented. The motion was seconded by Mr. Shaw, and the motion passed as follows:

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes- No- Abstain)	Abstained Board Members
1	Fernando Ibarra	T	ABO	2024-02655	8-0-0	-
2	Courtney Marie Lipton	T	ABO	2024-01731	6-0-2	Fernandez, Lewis
3	Janeth Elisa Arevalo	T	ABO	2024-00864	6-0-2	Montemayor, Yoakum
4	Alejandro Paola Mata	T	ABO	2024-02120	6-0-2	Martin, Shaw
5	Jacqueline Barcenas	T	ABO	2024-03918	7-0-1	Tijerina
6	John Anthony Botello	T	ABO	2024-03519	7-0-1	Tijerina
7	Gabriella Andrea Coy-Galindo	T	ABO	2024-04236	7-0-1	Tijerina
8	Stephanie Lynn Gest	T	ABO	2024-01032	7-0-1	Tijerina
9	Charles Hill	T	ABO	2023-05286	8-0-0	-
10	Deja Hill	T	ABO	2024-02122	8-0-0	-
11	Bridget K. Mahaffey	T	ABO	2024-02432	7-0-1	Tijerina
12	La'Donna Raquel Martin	T	ABO	2024-03565	7-0-1	Tijerina
13	Patty Juneann McEntyre	T	ABO	2024-04383	7-0-1	Tijerina
14	Jason Allen Benson	T	ABO	2024-05444	6-0-2	Fernandez, Lewis
15	Damisha Bonds	T	ABO	2024-04837	6-0-2	Fernandez, Lewis
16	Tukessa Glover	T	ABO	2024-04399	6-0-2	Fernandez, Lewis
17	Michelle Waynette Lane	T	ABO	2024-05023	6-0-2	Fernandez, Lewis
18	Diana Macedo	T	ABO	2024-05338	6-0-2	Fernandez, Lewis
19	Chrystelle Sike Wako	T	ABO	2024-04026	6-0-2	Fernandez, Lewis

\*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes- No- Abstain)	Abstained Board Members
20	Hilda N. Gamez	T	DBO	2024-05640	8-0-0	-
21	Holly J. Haskins	T	DBO	2024-01317	8-0-0	-
22	Brittany Dyann Hopkins	T	DBO	2023-04970	7-0-1	Tijerina
23	Ja'tasia La'veen Raglon	T	DBO	2023-07196	7-0-1	Tijerina
24	Charlotte Elaine Guthrie	T	DBO	2023-06997	6-0-2	Fernandez, Lewis
25	Rikki Thompson	T	DBO	2024-05472	6-0-2	Martin, Montemayor
26	Alto Pharmacy	P	ABO	2024-01512	8-0-0	-
27	Evan Christopher Brummert	R	ABO	2024-04057	8-0-0	-
28	CVS/pharmacy #7664	P	ABO	2024-03426	7-0-1	Tijerina
29	IsoRx San Angelo	P	ABO	2024-03753	8-0-0	-
30	Pharmacia Henrique	P	ABO	2024-03480	8-0-0	-
31	Rehabilitation Institute of South San Antonio	P	ABO	2023-07297	8-0-0	-
32	Walgreens #04418	P	ABO	2024-00510	7-0-1	Fernandez
33	Walgreens #04999	P	ABO	2024-03742	7-0-1	Fernandez
34	Walmart Pharmacy 10-1347	P	ABO	2024-03721	8-0-0	-
35	CVS/Caremark or CarelonRx Mail	P	ABO	2024-00775	5-0-3	Fernandez, Lewis, Tijerina
36	CVS/pharmacy #10535	P	ABO	2023-03351	5-0-3	Montemayor, Shaw, Tijerina
37	Cassandra Nicole Castillo	R	ABO	2023-07107	5-0-3	Montemayor, Shaw, Tijerina
38	Prem Swaroop Kalidindi	R	ABO	2024-00029	6-0-2	Lewis, Shaw
39	Walgreens #13116	P	ABO	2023-03337	5-0-3	Fernandez, Lewis, Shaw
40	Joseph Anthony Chimienti	R	ABO	2024-04376	7-0-1	Lewis
41	Medrock Pharmacy LLC	P	ABO	2024-01735	7-0-1	Lewis
42	Esther H. Cohen	R	ABO	2024-03194	6-0-2	Fernandez, Lewis
43	CVS/pharmacy #7650	P	ABO	2024-00231	5-0-3	Fernandez, Lewis, Tijerina
44	CVS/pharmacy #10635	P	ABO	2023-05266	5-0-3	Fernandez, Lewis, Tijerina
45	Wayne Allen Ewens	R	ABO	2023-06862	6-0-2	Fernandez, Lewis
46	Gregory Eugene Wickwire	R	ABO	2024-03925	6-0-2	Martin, Montemayor
47	DCP Health	P	DBO	2024-03819	6-0-2	Fernandez, Lewis
48	Community of Houston Pharmacy LLC	P	DBO	2023-02391	6-0-2	Fernandez, Yoakum
49	Vincent Ikechi Nwabeke	R	ABO	2024-00405	7-0-1	Yoakum
50	<i>Confidential</i>	R	ABO	2024-05194	8-0-0	-
51	<i>Confidential</i>	R	ABO	2024-02943	6-0-2	Lewis, Shaw

\*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

No.	Name	T, I, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes- No- Abstain)	Abstained Board Members
52	<i>Confidential</i>	R	ABO	2024-06439	6-0-2	Fernandez, Lewis
53	Daniel Contreras	R	RP	2024-05112	8-0-0	-
54	Diana Anh Thu Davenport	R	RP	2024-04631	8-0-0	-
55	Lashunda Ann Hinton	R	RP	2024-02796	8-0-0	-
56	Jason Eric Kessler	R	RP	2024-02685	8-0-0	-
57	Vu Xuan Nguyen	R	RP	2024-04725	8-0-0	-
58	North Park Pharmacy	P	RP	2024-02317	8-0-0	-
59	River Pointe Pharmacy	P	RP	2024-04575	8-0-0	-
60	Harshpreet Dhillon	R	RP	2024-04844	8-0-0	-
61	Kimberly Truong	R	RP	2024-04669	8-0-0	-
62	Windrose Rx	P	RP	2024-02787	8-0-0	-
63	Nelson Origa	R	RP	2023-05989	6-0-2	Lewis, Shaw
64	Mekason Pharmacy	P	RP	2024-02335	7-0-1	Lewis
65	Emeka Magnus Onyemetu	R	RP	2024-04268	7-0-1	Lewis
66	Ladislao Cardenas	R	RP	2023-05836	6-0-2	Fernandez, Lewis
67	Medhin Haile Getachew	R	RP	2024-03203	6-0-2	Fernandez, Lewis
68	Alena Nguyen	R	RP	2024-02322	6-0-2	Fernandez, Lewis
69	Oluremi Mojisola Olukoya	R	RP	2024-05112	6-0-2	Fernandez, Lewis
70	Lea Ann Whiddon	R	RP	2024-02683	6-0-2	Fernandez, Lewis

\*Technician or Technician Trainee (T), Pharmacist Intern (I), Pharmacist (R), and Pharmacy (P)

\*\*Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

President Spier recessed the meeting at 1:57 p.m.  
President Spier reconvened the meeting at 2:20 p.m.

**C. Discussion of and Possible Action Regarding Rules, continued**

Final Adoption of Rules, continued

- Rules Concerning Pharmacies Compounding Sterile Preparations (§291.133) (Item C.1.3), continued

Ms. Holloway reviewed suggested modifications to the proposed amendments to §291.133, based on comments received.

Discussion concerning the proposed amendments to §291.133 continued, which included a review of proposed changes to media-fill testing, sterility testing, and beyond-use-dating.

President Spier announced that the Board would go into Executive Session for the purpose of consulting with legal counsel under the authority of the Texas Government Code, §551.071.

President Spier declared the Board in Executive Session at 3:53 p.m.

At 4:24 p.m., President Spier announced that the Board would resume the meeting in Open Session and that no action was taken and no decisions were made during Executive Session.

Following discussion, the motion was made by Mr. Lewis to approve for proposal the amendments to §291.133, with the modifications set forth in discussion. The motion was seconded by Mr. Shaw and passed unanimously.

**I. Miscellaneous**

- Items to be Placed on Agenda for February 4, 2025, Board Meeting (Item I.1)

President Spier requested Board members to submit any additional items for the February 4, 2025, Board meeting to staff.

- Discussion of and Possible Action on Upcoming Conferences and Events (Item I.2)

President Spier reviewed upcoming meetings and conferences.

**J. Consideration of Personnel Matters**

- Executive Session to Conduct Evaluation of Executive Director (Item J.1)

President Spier announced that the Board would go into Executive Session to consider personnel matters under the authority of the Texas Government Code, §551.074.


President Spier declared the Board in Executive Session at 4:45 p.m.

At 5:12 p.m., President Spier announced that the Board would resume the meeting in Open Session and that no action was taken and no decisions were made during Executive Session.

Mr. Shaw made a motion to adjourn the meeting. The motion was seconded by Mr. Fernandez and passed unanimously.


President Spier adjourned the meeting at 5:13 p.m.

APPROVED:



---

Julie Spier, R.Ph.  
President



---

Daniel Carroll, Pharm.D., R.Ph.  
Executive Director/Secretary

February 4, 2025